A Note From Our CEO & Founder
"In life sciences and healthcare, the most consequential moments often come when a financing decision, transaction, or operating transition becomes too important to manage off the side of the leadership team's desk.
ClarityNorth Partners was built for those moments. We provide the senior judgment and execution capacity needed to evaluate strategic options, prepare decisively, execute transactions, and translate them into lasting value.
Our role is simple: help management teams stay in control when the stakes are highest."
— Sebastian Andersen
Sebastian Andersen is a senior advisor in corporate development, M&A, and transformation with over a decade of experience supporting leading life sciences and healthcare companies across the corporate lifecycle.
His work spans biopharma, MedTech, advanced therapies, tools and services, healthcare, and specialty chemicals, where he has partnered with corporate and private equity clients to execute landmark transactions and complex operating transformations across Europe and the Americas.
He has advised on capital readiness, divestitures, carve-outs, integrations, transaction execution, and post-close operating models. Known for his pragmatic, hands-on approach, Sebastian focuses on bridging strategic decisions and execution to help leadership teams deliver through critical inflection points.
About ClarityNorth Partners
At ClarityNorth Partners, we believe critical corporate-development moments demand more than advice. They require senior judgment, disciplined execution, and the ability to translate strategic decisions into transactions and operating change.
Founded in New York City with global experience, we work with management teams, boards, sponsors, and corporate leaders across biopharma, MedTech and diagnostics, healthcare technology and AI, and life-sciences services. Our engagements are typically driven by a capital event, partnering or licensing decision, acquisition or divestiture, carve-out, integration, or portfolio decision.
Senior-led and execution-focused, we provide additional corporate development and transaction capacity when the demands of a critical event exceed the capacity or capabilities available internally. From strategic alternatives and capital readiness through transaction execution, Day 1, integration, and value creation, we help clients stay in control before, during, and after strategic transactions.
Depth Where It Counts. Experience That Delivers.
At ClarityNorth Partners, our work is driven by the experience and judgment of our advisors. Our team brings together strategic, transaction, and scientific expertise across the life sciences and healthcare sector.
Our advisors include Executive Strategy & M&A Advisors and Senior Strategy & M&A Advisors. Our advisors hold Executive MBA degrees, MDs, and PhDs and have built careers across venture capital, corporate development, strategic advisory, and industry leadership roles.
Collectively, our team brings years of experience and more than US$ 25 billion in transaction value supporting companies through capital raises, partnerships, operational scale-ups, and strategic transactions.
Sebastian Andersen
CEO & Founder
Sebastian Andersen is the Founder of ClarityNorth Partners and an advisor focused on strategy, capital markets, and M&A. He works with leaders on capital raising, strategic partnerships, and transactions, helping companies position themselves for growth, investment, or strategic transactions.
Victor Dong, MD, SFMBA
Executive Strategy and M&A Advisor
Dr. Dong is a Harvard trained physician specialist and MIT Sloan Fellows MBA 2026 with deep clinical expertise and a distinguished career in global drug development at Novartis. His passion lies at the intersection of life sciences and healthcare venture capital, AI, and entrepreneurship.
Federico Oldoni, PhD, MBA
Executive Strategy and M&A Advisor
Dr. Oldoni holds a PhD and an MBA, with experience in translational research and drug development across multiple therapeutic indications. He focuses on science, business development, strategy, and venture capital in the early-stage biotech ecosystem.
Omar Abbas, MD
Senior Strategy and M&A Advisor
Dr. Abbas is a physician with expertise in precision medicine, oncology diagnostics, and digital health. He combines clinical experience in Pathology with advisory work across life sciences strategy, venture capital diligence and strategic build-up, and transactions.
Dr. Brenda Melano
Senior Strategy and M&A Advisor
Dr. Melano is a UCSF-trained scientist and biotech advisor focused on strategy and transaction support. Her experience spans biomedical research, venture capital due diligence, company building and public equity research.
Emily Thomas, EMBA
Senior Strategy and M&A Advisor
Emily is an advisor focused on strategy and operations across growth-stage companies. She brings experience translating strategic priorities into operational execution, leading cross-functional initiatives, aligning leadership teams, and supporting organizations as they scale.
Nikola Gostovic
Senior Strategy and M&A Advisor
Nikola is an advisor focused on strategy, transactions, and growth across life sciences and healthcare. He brings experience from investment, corporate strategy, and advisory roles, supporting companies and investors on capital strategy, partnerships, and strategic positioning.
Our Ecosystem, Network, and Extended Bench
ClarityNorth Partners is deeply embedded in the global life sciences and healthcare investment ecosystem. Our network spans the full spectrum of subsectors, including biopharma, medtech, advanced therapies, tools and services, healthcare, and specialty chemicals.
We work across every major investor category, from venture capital, private equity, and family offices to corporate and strategic investors, institutional investors, and sovereign or government funds. Our reach also extends to buyers and acquirers as well as non-traditional capital partners such as incubators, accelerators, innovation hubs, and impact funds.
By bridging science and capital, we give our clients, whether they are in a pre-clinical discovery stage or are mature and commercial companies, access to a diverse ecosystem of investors and partners, helping them accelerate growth, scale innovation, and unlock long-term value.
Why ClarityNorth Partners
Companies that understand true deal value lies in preparation and hands-on execution, and that this demands senior-level attention to make a lasting impact, choose ClarityNorth Partners.
As your partner, we’re driven by six core principles that shape how we operate and how we deliver results. These principles are more than values. They’re how we execute, how we collaborate, and how we lead change in every engagement.
Clarity in Execution
We bring structure to complexity and force clear priorities early. Our work is designed to eliminate ambiguity so management teams can focus on the decisions that actually move value.
Respect the People Side
Transactions and capital events are change events. We understand the human, leadership, and trust dynamics that sit beneath execution, and manage them deliberately.
Operate at Pace
We move with urgency, not noise. We help teams make fast, informed decisions under pressure without losing control or strategic discipline.
Precision Over Polish
We prioritize accuracy, judgment, and usability over buzzwords and presentation gloss. Our work is built to withstand scrutiny from investors, boards, and counterparties.
Think Like Owners
We think in terms of outcomes, not deliverables. We treat capital, time, and credibility as scarce resources and act accordingly, aligning every decision to long-term value creation, not short-term optics.
Build for Day 2, Not Just Day 1
We design strategies and processes that hold up after the announcement. Our focus is on integration, separation, scale, and durability and not just getting a deal or round done.